These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 15017380

  • 21. The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma.
    Van Houdt WJ, Haviv YS, Lu B, Wang M, Rivera AA, Ulasov IV, Lamfers ML, Rein D, Lesniak MS, Siegal GP, Dirven CM, Curiel DT, Zhu ZB.
    J Neurosurg; 2006 Apr; 104(4):583-92. PubMed ID: 16619663
    [Abstract] [Full Text] [Related]

  • 22. Growth factor-dependent regulation of survivin by c-myc in human breast cancer.
    Cosgrave N, Hill AD, Young LS.
    J Mol Endocrinol; 2006 Dec; 37(3):377-90. PubMed ID: 17170079
    [Abstract] [Full Text] [Related]

  • 23. Suppression of tumor growth using a recombinant adenoviral vector carrying the dominant-negative mutant gene Survivin-D53A in a nude mice model.
    Zhu DE, Höti N, Song Z, Jin L, Wu Z, Wu Q, Wu M.
    Cancer Gene Ther; 2006 Aug; 13(8):762-70. PubMed ID: 16543917
    [Abstract] [Full Text] [Related]

  • 24. Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma.
    Barker SD, Dmitriev IP, Nettelbeck DM, Liu B, Rivera AA, Alvarez RD, Curiel DT, Hemminki A.
    Gene Ther; 2003 Jul; 10(14):1198-204. PubMed ID: 12833129
    [Abstract] [Full Text] [Related]

  • 25. Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors.
    Müller OJ, Leuchs B, Pleger ST, Grimm D, Franz WM, Katus HA, Kleinschmidt JA.
    Cardiovasc Res; 2006 Apr 01; 70(1):70-8. PubMed ID: 16448634
    [Abstract] [Full Text] [Related]

  • 26. Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells.
    Sakoguchi-Okada N, Takahashi-Yanaga F, Fukada K, Shiraishi F, Taba Y, Miwa Y, Morimoto S, Iida M, Sasaguri T.
    Biochem Pharmacol; 2007 May 01; 73(9):1318-29. PubMed ID: 17270149
    [Abstract] [Full Text] [Related]

  • 27. Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers.
    Yamamoto M, Alemany R, Adachi Y, Grizzle WE, Curiel DT.
    Mol Ther; 2001 Mar 01; 3(3):385-94. PubMed ID: 11273781
    [Abstract] [Full Text] [Related]

  • 28. Tumor-specific adenoviral gene therapy: transcriptional repression of gene expression by utilizing p53-signal transduction pathways.
    Kühnel F, Zender L, Wirth T, Schulte B, Trautwein C, Manns M, Kubicka S.
    Cancer Gene Ther; 2004 Jan 01; 11(1):28-40. PubMed ID: 14681724
    [Abstract] [Full Text] [Related]

  • 29. Tumor-specific therapeutic effect induced by an oncolytic adenoviral vector containing heat shock protein 70 and prodrug activation genes.
    Liu Y, Ye T, Sun D, Maynard J, Deisseroth A.
    Gene Ther; 2006 Aug 01; 13(16):1235-43. PubMed ID: 16617300
    [Abstract] [Full Text] [Related]

  • 30. Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells.
    Siders WM, Halloran PJ, Fenton RG.
    Cancer Res; 1996 Dec 15; 56(24):5638-46. PubMed ID: 8971169
    [Abstract] [Full Text] [Related]

  • 31. Cancer-specific activation of the survivin promoter and its potential use in gene therapy.
    Chen JS, Liu JC, Shen L, Rau KM, Kuo HP, Li YM, Shi D, Lee YC, Chang KJ, Hung MC.
    Cancer Gene Ther; 2004 Nov 15; 11(11):740-7. PubMed ID: 15359286
    [Abstract] [Full Text] [Related]

  • 32. An oncolytic adenoviral vector carrying the tyrosinase promoter for glioma gene therapy.
    Ulasov IV, Rivera AA, Nettelbeck DM, Rivera LB, Mathis JM, Sonabend AM, Tyler M, Wang M, Douglas JT, Lesniak MS.
    Int J Oncol; 2007 Nov 15; 31(5):1177-85. PubMed ID: 17912445
    [Abstract] [Full Text] [Related]

  • 33. Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.
    Spinella F, Rosanò L, Di Castro V, Nicotra MR, Natali PG, Bagnato A.
    Clin Cancer Res; 2004 Jul 15; 10(14):4670-9. PubMed ID: 15269139
    [Abstract] [Full Text] [Related]

  • 34. Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells.
    Dong K, Wang R, Wang X, Lin F, Shen JJ, Gao P, Zhang HZ.
    Breast Cancer Res Treat; 2009 Feb 15; 113(3):443-56. PubMed ID: 18327707
    [Abstract] [Full Text] [Related]

  • 35. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression.
    Kuppuswamy M, Spencer JF, Doronin K, Tollefson AE, Wold WS, Toth K.
    Gene Ther; 2005 Nov 15; 12(22):1608-17. PubMed ID: 16034456
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Krüppel-like factor 4 represses transcription of the survivin gene in esophageal cancer cell lines.
    Zhang G, Zhu H, Wang Y, Yang S, Liu M, Zhang W, Quan L, Bai J, Liu Z, Xu N.
    Biol Chem; 2009 Nov 15; 390(5-6):463-9. PubMed ID: 19361279
    [Abstract] [Full Text] [Related]

  • 39. [Gene therapy targeting for carcinoma regulated by E2F-1 promoter].
    Zhang XW, Meng ZH, Zhao JS, Zhang D, Xie YJ, Gao SH, Wang CY.
    Zhonghua Wai Ke Za Zhi; 2006 Dec 01; 44(23):1636-9. PubMed ID: 17359698
    [Abstract] [Full Text] [Related]

  • 40. Survivin-responsive conditionally replicating adenovirus exhibits cancer-specific and efficient viral replication.
    Kamizono J, Nagano S, Murofushi Y, Komiya S, Fujiwara H, Matsuishi T, Kosai K.
    Cancer Res; 2005 Jun 15; 65(12):5284-91. PubMed ID: 15958575
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.